BR112012030941A2 - proteína de fusão tendo atividade de fator vii - Google Patents
proteína de fusão tendo atividade de fator viiInfo
- Publication number
- BR112012030941A2 BR112012030941A2 BR112012030941A BR112012030941A BR112012030941A2 BR 112012030941 A2 BR112012030941 A2 BR 112012030941A2 BR 112012030941 A BR112012030941 A BR 112012030941A BR 112012030941 A BR112012030941 A BR 112012030941A BR 112012030941 A2 BR112012030941 A2 BR 112012030941A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion protein
- factor vii
- vii activity
- activity
- factor
- Prior art date
Links
- 229940012413 factor vii Drugs 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100052719 | 2010-06-04 | ||
| PCT/KR2011/004131 WO2011152694A2 (en) | 2010-06-04 | 2011-06-07 | Fusion protein having factor vii activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012030941A2 true BR112012030941A2 (pt) | 2017-06-06 |
Family
ID=45067214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012030941A BR112012030941A2 (pt) | 2010-06-04 | 2011-06-07 | proteína de fusão tendo atividade de fator vii |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9644197B2 (pt) |
| EP (1) | EP2576625B1 (pt) |
| JP (2) | JP6143297B2 (pt) |
| KR (1) | KR101331101B1 (pt) |
| CN (2) | CN103068854A (pt) |
| AU (1) | AU2011262494B2 (pt) |
| BR (1) | BR112012030941A2 (pt) |
| CA (1) | CA2801223C (pt) |
| ES (1) | ES2676874T3 (pt) |
| MX (1) | MX348567B (pt) |
| RU (1) | RU2585231C2 (pt) |
| WO (1) | WO2011152694A2 (pt) |
| ZA (1) | ZA201300066B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6143297B2 (ja) | 2010-06-04 | 2017-06-07 | チウムバイオ・カンパニー・リミテッドＴｉｕｍＢｉｏ Ｃｏ．， Ｌｔｄ． | 第ｖｉｉ因子活性を有する融合タンパク質 |
| DK3241558T3 (da) * | 2010-09-28 | 2021-04-26 | Aegerion Pharmaceuticals Inc | Højopløselige leptiner |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| WO2014129876A1 (ko) | 2013-02-25 | 2014-08-28 | 에스케이케미칼주식회사 | 인자 vii을 포함하는 융합 단백질의 분리 및 정제 방법 |
| KR102058864B1 (ko) * | 2013-12-16 | 2019-12-24 | 주식회사 티움바이오 | 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물 |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| CA3073317A1 (en) | 2017-08-18 | 2019-02-21 | Neutrolis Therapeutics, Inc. | Engineered dnase enzymes and use in therapy |
| WO2019087792A1 (ja) | 2017-10-30 | 2019-05-09 | パナソニックＩｐマネジメント株式会社 | 棚札検出装置、棚札検出方法、及び、棚札検出プログラム |
| US10988746B2 (en) * | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
| SG11202103426XA (en) | 2018-10-08 | 2021-05-28 | Neutrolis Inc | Engineering of dnase enzymes for manufacturing and therapy |
| CN110229237A (zh) * | 2019-06-24 | 2019-09-13 | 王跃驹 | 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用 |
| CN110218259B (zh) * | 2019-06-24 | 2022-09-16 | 王跃驹 | 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| RU2278123C2 (ru) | 2000-02-11 | 2006-06-20 | Максиджен Холдингз Лтд. | Молекулы, подобные фактору vii или viia |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| CN101177456A (zh) * | 2001-08-30 | 2008-05-14 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| US20040023334A1 (en) | 2001-08-30 | 2004-02-05 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| US7125843B2 (en) * | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| UA81114C2 (en) | 2002-05-01 | 2007-12-10 | Schering Ag | Novel antibodies to tissue factor as anticoagulants |
| AU2003262886A1 (en) * | 2002-08-30 | 2004-03-19 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
| US20070072271A1 (en) * | 2004-01-07 | 2007-03-29 | Novo Nordisk Healthcare A/G | Method for the production of recombinant proteins |
| EP1816201A1 (en) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| DK2004683T3 (en) * | 2006-03-24 | 2016-08-22 | Biogen Hemophilia Inc | PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM |
| GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| US7943733B2 (en) | 2007-12-20 | 2011-05-17 | University Of Southern California | Spacers to increase the expression of recombinant fusion proteins |
| EP2926825A1 (en) | 2008-06-27 | 2015-10-07 | Duke University | Therapeutic agents comprising elastin-like peptides |
| WO2011070484A2 (en) * | 2009-12-08 | 2011-06-16 | Koninklijke Philips Electronics N.V. | A method and a correction system for correcting tracer-uptake measurements |
| JP6143297B2 (ja) | 2010-06-04 | 2017-06-07 | チウムバイオ・カンパニー・リミテッドＴｉｕｍＢｉｏ Ｃｏ．， Ｌｔｄ． | 第ｖｉｉ因子活性を有する融合タンパク質 |
-
2011
- 2011-06-07 JP JP2013513120A patent/JP6143297B2/ja not_active Expired - Fee Related
- 2011-06-07 RU RU2012157301/10A patent/RU2585231C2/ru active
- 2011-06-07 ES ES11790052.2T patent/ES2676874T3/es active Active
- 2011-06-07 EP EP11790052.2A patent/EP2576625B1/en active Active
- 2011-06-07 MX MX2012013807A patent/MX348567B/es active IP Right Grant
- 2011-06-07 CN CN2011800277076A patent/CN103068854A/zh active Pending
- 2011-06-07 AU AU2011262494A patent/AU2011262494B2/en active Active
- 2011-06-07 CN CN201710403215.1A patent/CN107188970A/zh active Pending
- 2011-06-07 CA CA2801223A patent/CA2801223C/en active Active
- 2011-06-07 KR KR1020110054573A patent/KR101331101B1/ko active IP Right Grant
- 2011-06-07 WO PCT/KR2011/004131 patent/WO2011152694A2/en active Application Filing
- 2011-06-07 US US13/701,333 patent/US9644197B2/en active Active
- 2011-06-07 BR BR112012030941A patent/BR112012030941A2/pt not_active Application Discontinuation
-
2013
- 2013-01-03 ZA ZA2013/00066A patent/ZA201300066B/en unknown
-
2016
- 2016-03-25 US US15/080,757 patent/US10696960B2/en active Active
- 2016-07-01 JP JP2016131637A patent/JP6422918B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110133454A (ko) | 2011-12-12 |
| US20130236945A1 (en) | 2013-09-12 |
| CN107188970A (zh) | 2017-09-22 |
| JP2017000144A (ja) | 2017-01-05 |
| EP2576625B1 (en) | 2018-04-25 |
| RU2585231C2 (ru) | 2016-05-27 |
| WO2011152694A8 (en) | 2013-01-17 |
| WO2011152694A2 (en) | 2011-12-08 |
| WO2011152694A3 (en) | 2012-04-19 |
| MX348567B (es) | 2017-06-20 |
| AU2011262494A2 (en) | 2013-08-01 |
| CA2801223A1 (en) | 2011-12-08 |
| EP2576625A4 (en) | 2013-11-06 |
| ZA201300066B (en) | 2014-03-26 |
| RU2012157301A (ru) | 2014-07-20 |
| MX2012013807A (es) | 2012-12-17 |
| US20160194622A1 (en) | 2016-07-07 |
| CA2801223C (en) | 2019-12-03 |
| AU2011262494A1 (en) | 2013-01-24 |
| JP2013529914A (ja) | 2013-07-25 |
| EP2576625A2 (en) | 2013-04-10 |
| CN103068854A (zh) | 2013-04-24 |
| US10696960B2 (en) | 2020-06-30 |
| US9644197B2 (en) | 2017-05-09 |
| ES2676874T3 (es) | 2018-07-25 |
| JP6143297B2 (ja) | 2017-06-07 |
| JP6422918B2 (ja) | 2018-11-14 |
| KR101331101B1 (ko) | 2013-11-19 |
| AU2011262494B2 (en) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012030941A2 (pt) | proteína de fusão tendo atividade de fator vii | |
| ES2551605T5 (es) | Preparaciones de anticuerpos | |
| BR112013013663A2 (pt) | ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização | |
| DK2536830T3 (da) | Polypeptider | |
| CO6491031A2 (es) | Proteinas de fusion actriib-fc truncadas | |
| BR112012030311A2 (pt) | anticorpo | |
| DK2598514T3 (da) | Proteinoprensning | |
| BR112013013548A2 (pt) | proteína de fusão anticancerígena | |
| CO6791565A2 (es) | Anticuerpos anti-notch1 | |
| BR112012005389A2 (pt) | preparações pesticidas | |
| BR112013008347A2 (pt) | polipeptídeos de variantes cbh i | |
| SG10201500208SA (en) | Npp1 fusion proteins | |
| BR302012001179S1 (pt) | "configuração aplicada em farol" | |
| EP2657337A4 (en) | FUSION PROTEIN | |
| FI20116212A (fi) | Polypeptidi | |
| EP2631249A4 (en) | FUSION PROTEIN WITH FACTOR IX EFFECT | |
| DK2590565T3 (da) | Blodprøvetagning | |
| DK3392268T3 (da) | Polypeptider med transgalactosylerende aktivitet | |
| FI20100404A0 (fi) | Yhteysalus | |
| BR112013012390A2 (pt) | hidrolisado de proteína hidrofobizada | |
| BR302012001168S1 (pt) | "configuração aplicada em farol" | |
| DE112011103890A5 (de) | Verbindungsanordnung | |
| ZA201207425B (en) | Fusion protein | |
| IT1402256B1 (it) | Filtro e procedimento per la sua realizzazione. | |
| FIU20100501U0 (fi) | Yhteysalus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: TIUMBIO CO., LTD. (KR) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |